CRNA — Circio Holding ASA Share News
0.000.00%
Last trade - 00:00- NOK1.79bn
- NOK1.80bn
Brief: Circio Requests Bridge Financing From Atlas
Brief: Circio To Raise Up To About NOK 52 Mln In Rights Issue
Brief: Circio: In Vivo Proof-Of-Concept For Circvec Circular RNA Platform Technology
Brief: Circio To Raise Around NOK 50-60 Million In Q2 2024
Brief: Circio Ends TG01 Cancer Vaccine License Option Agreement
Brief: Circio Holding's Partner IOVaxis Therapeutics Exercises Option For Exclusive License
Brief: Circio Holding Says Atlas Requests Conversion Of Convertible Bonds
Brief: Circio Receives Waiver Of EUR 6.2 Million In Loans From Business Finland
Brief: Circio Announces Outcome Of EU Patent Proceeding
Brief: Circio To Test Combination Of TG01 Vaccination With Daratumumab And Nivolumab
Brief: Circio To Close Unit In Finland, Reduce BoD
Brief: Circio To Collaborate With Neoregen Biotech
Brief: Circio Holding H1 Operating Loss Widens To NOK 72.5 Million
Brief: Circio Holding ASA Says Atlas Requested Conversion Of Convertible Bonds
Brief: Targovax To Rebrand As Circio
Brief: Targovax Says Prioritize Resources On Unlocking The Potential Of Its Circrna Platform
Brief: Targovax Q4 Net Loss NOK 22.2 Million
Brief: Targovax Says Financing Of Up To NOK 300 Mln Over Three Years To Advance Its Clinical Cancer Programs & Pre-Clinical Circular RNA Platform
Brief: Targovax Announces Clinical Trial Collaboration With Agenus